In one study comparison of 11 de novo CD5+ DLBCL and 9 CD5− DLBCL cases showed upregulation of integrin-β 1 and/or CD36 adhesion molecules, which were confirmed by immunohistochemistry (IHC) to be expressed in tumor cells and vascular endothelia, respectively [24]. Here, CD5 is linked to neoplasm.